Clinical Trials Browser

Recruiting × Lung Neoplasms × Cyclophosphamide × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02133196 2026-03-24

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06885697 2026-02-17

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Phase 1 Recruiting

100 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

NCT06538012 2024-10-15

BAH2472

Phase 1/2 Recruiting

85 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

PNeoVCA

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

BAH2472